Federated Hermes’s Jasper Therapeutics JSPR Stock Holding History

Federated Hermes’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.39K	Sell	3,868 -1,079	-22%	-$1.5K	﹤0.01%	1931
2025 Q4	$9.05K	Buy	4,947 +2,150	+77%	+$4.32K	﹤0.01%	1841
2025 Q3	$6.66K	Buy	2,797 +820	+41%	+$2.49K	﹤0.01%	1915
2025 Q2	$11K	Buy	1,977 +920	+87%	+$4.53K	﹤0.01%	1807
2025 Q1	$4.54K	Buy	+1,057	New	+$7.03K	﹤0.01%	1884
2022 Q2	–	Sell	-25,170	Closed	-$894K	–	2224
2022 Q1	$894K	Sell	25,170 -95,488	-79%	-$4.3M	﹤0.01%	1288
2021 Q4	$9.47M	Sell	120,658 -29,342	-20%	-$2.75M	0.02%	661
2021 Q3	$12.5M	Buy	+150,000	New	+$15.3M	0.02%	593

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Federated Hermes's JSPR Position: Q1 2026 in Review

Federated Hermes reduced its Jasper Therapeutics (JSPR) stake by 22% in Q1 2026, selling an estimated $1.5K and leaving 3,868 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

Federated Hermes first reported a position in JSPR in Q3 2021 and has held it in 8 quarters since. The position peaked at $12.5M in Q3 2021. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Federated Hermes held 3,868 shares of Jasper Therapeutics worth $3.39K as of Q1 2026.
Federated Hermes sold 1,079 Jasper Therapeutics shares in Q1 2026, an estimated $1.5K.
Jasper Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1931 holding.
Federated Hermes first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 8 quarters since.
Federated Hermes's Jasper Therapeutics position peaked at $12.5M in Q3 2021.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.